Technology

Technology

Priavoid uses image phage display selection and various optimization technologies to develop all-D-peptides, compounds composed exclusively of D-enantiomeric (mirror image) amino acids. In contrast to natural peptides consisting of L-amino acids, all-D-peptides are resistant to proteases and are degraded very slowly. Therefore, they can be administered orally, for example as a tablet.

Pre-clinical and clinical trials are pursued at Priavoid for the development of drugs for treatment of neurodegenerative diseases.

Pipeline

The drug pipeline of Priavoid is composed of 6 compounds in development with 5 CNS diseases